POSITIVE IN VITRO DATA FOR CHM 1301 CAR NK CELLS IN OVARIAN AND
PANCREATIC CANCERS
Positive preclinical data for CHM 1301, a next generation off the shelf CLTX CAR NK cell therapy
Up to 300% enhanced cell killing demonstrated compared to first generation NK cells
Evidence of expansion into two new solid tumours – pancreatic cancer and ovarian cancer
CHM 1301 program to advance to the next stage of preclinical development under academic
research collaboration
POSITIVE IN VITRO DATA FOR CHM 1301 CAR NK CELLS IN OVARIAN AND...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $8.917K | 2.229M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 6067085 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 17489088 | 18 |
View Market Depth
| Last trade - 16.10pm 30/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |